NCT06878469 SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence
| NCT ID | NCT06878469 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta |
| Condition | Brain Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-01-27 |
| Primary Completion | 2025-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-01-27 with a primary completion date of 2025-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study focuses on rare brain tumors, which are heterogeneous entities with different morphological, biological, and clinical characteristics. Due to their rarity, many of these tumors fall under the RARECARE definition of rare tumors. The main objective of the study is to standardize care models and pathways for patients with rare brain tumors, using Artificial Intelligence (AI) and Machine Learning (ML) techniques to identify specific predictors of postoperative outcomes. The study includes both retrospective and prospective phases, with the collection of clinical, cognitive, and psychological data at various time points. Patients will undergo an early neuro-cognitive rehabilitation program using the RehaCom software, which will be conducted at home. The goal is to improve the quality of life and care for patients through a multidisciplinary and innovative approach.
Eligibility Criteria
Inclusion Criteria: * Adults (age ≥18 years) * Both sexes * Patients with rare brain tumors (incidence \<6 cases per 100,000 people/year) * Candidates for craniotomy for rare brain tumors * Native Italian speakers for cognitive and psychological evaluation and neuro-cognitive rehabilitation Exclusion Criteria: * Patients undergoing stereotactic/frameless biopsy * Patients with psychiatric disorders or on psychotropic medications * Patients with known cognitive decline (not due to the lesion) * Patients admitted on the same day as the surgery * Patients with severe impairments referred to rehabilitation centers * Patients without a Windows PC or laptop with Internet connection for neuro-cognitive rehabilitation
Contact & Investigator
Paolo Ferroli, MD
PRINCIPAL INVESTIGATOR
Fondazione IRCCS Istituto Neurologico Carlo Besta
Frequently Asked Questions
Who can join the NCT06878469 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06878469 currently recruiting?
Yes, NCT06878469 is actively recruiting participants. Contact the research team at giorgia.camarda@istituto-besta.it for enrollment information.
Where is the NCT06878469 trial being conducted?
This trial is being conducted at Milan, Italy, L’Aquila, Italy.
Who is sponsoring the NCT06878469 clinical trial?
NCT06878469 is sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. The principal investigator is Paolo Ferroli, MD at Fondazione IRCCS Istituto Neurologico Carlo Besta. The trial plans to enroll 200 participants.